Merseyside Inter Agency Drug Misuse Database

January - March 2011

St Helens DAT

Quarter 4 2010/11

Martin Chandler and Steven Griffith

DRAFT REPORT
The final version will be available on the IAD website

www.cph.org.uk/iad

Contacts:

Martin Chandler

IAD Manager

Centre for Public Health

Faculty of Health & Applied Social Sciences

Liverpool John Moores University

2nd Floor, Henry Cotton Campus,

15-21 Webster Street, Liverpool.

L3 2ET

(0151) 231 4349

m.chandler@ljmu.ac.uk

Steven Griffith

IAD Researcher

(0151) 231 4309

S.W.Griffith@ljmu.ac.uk

www.cph.org.uk/iad

Contents

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)
Quarter 4 (2010/11)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period. Data are based on initial contact in court or custody suites representing a sub section of the full DIP dataset, further information is available from the IAD on request.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	49	89.1
Female	6	10.9
Age Group		
Under 18	0	0.0
18-19	3	5.5
20-24	10	18.2
25-29	11	20.0
30-34	10	18.2
35-39	13	23.6
40-44	3	5.5
45+	5	9.1
Total	55	100

Table 2: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	11	4.6	3	9.4	14	5.2
20-24	57	23.9	2	6.3	59	21.9
25-29	56	23.5	5	15.6	61	22.6
30-34	44	18.5	9	28.1	53	19.6
35-39	36	15.1	7	21.9	43	15.9
40-44	18	7.6	5	15.6	23	8.5
45+	16	6.7	1	3.1	17	6.3
Total	238	100	32	100	270	100

Table 3: Reported Main Drug(s)* of Use, by Frequency of Use

Drug of Use	Daily	Weekly	Monthly
Amphetamines	1	1	0
Benzodiazepines	0	0	0
Cannabis	1	1	0
Crack	0	0	0
Cocaine	2	7	15
Ecstasy	0	0	0
Heroin	19	3	2
Methadone	0	0	0
Other	0	0	0

3 individuals did not report a main drug of use

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily, Weekly or Monthly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

NEEDLE AND SYRINGE PROGRAMMES
Quarter 4 (2010/11)

Introduction

Data are collected directly from needle and syringe programmes (NSPs). Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

Agency NSP Data were not received in time for inclusion in this report. The Quarter 3 (2010/11) report will include figures for quarter 2.

AGENCY NSP

Table 4: Individuals by Gender

New Clients	n	%
Male	61	95.3
Female	3	4.7
Total	64	100
All Clients		
Male	184	92.9
Female	14	7.1
Total	198	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	11	84.6
Female	2	15.4
Total	13	100
All Clients		
Male	60	82.2
Female	13	17.8
Total	73	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	3	4.7	3	1.5
18-19	5	7.8	6	3.0
20-24	20	31.3	45	22.7
25-29	11	17.2	35	17.7
30-34	8	12.5	33	16.7
35-39	1	1.6	23	11.6
40-44	12	18.8	34	17.2
45+	4	6.3	19	9.6
Total	64	100	198	100

Table 7 Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	7.7	8	11.0
25-29	1	7.7	6	8.2
30-34	1	7.7	10	13.7
35-39	0	0.0	9	12.3
40-44	7	53.8	24	32.9
45+	3	23.1	16	21.9
Total	13	100	73	100

Table 8: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	3	1.6	0	0.0
18-19	6	3.3	0	0.0
20-24	42	22.8	3	21.4
25-29	33	17.9	2	14.3
30-34	32	17.4	1	7.1
35-39	23	12.5	0	0.0
40-44	30	16.3	4	28.6
45+	15	8.2	4	28.6
Total	184	100	14	100

Table 9: Gender by Age Group: Steroid Users omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	6	10.0	2	15.4
25-29	4	6.7	2	15.4
30-34	9	15.0	1	7.7
35-39	9	15.0	0	0.0
40-44	20	33.3	4	30.8
45+	12	20.0	4	30.8
Total	60	100	13	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	3	< 1	0	0.0	3	< 1
18-19	24	5.0	3	6.5	27	5.1
20-24	99	20.5	4	8.7	103	19.4
25-29	88	18.2	10	21.7	98	18.5
30-34	87	18.0	7	15.2	94	17.7
35-39	82	16.9	7	15.2	89	16.8
40-44	66	13.6	6	13.0	72	13.6
45+	35	7.2	9	19.6	44	8.3
Total	484	100	46	100	530	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	< 1	0	0.0	1	< 1
20-24	12	6.9	3	8.1	15	7.1
25-29	14	8.0	8	21.6	22	10.4
30-34	32	18.3	7	18.9	39	18.4
35-39	44	25.1	5	13.5	49	23.1
40-44	45	25.7	5	13.5	50	23.6
45+	27	15.4	9	24.3	36	17.0
Total	175	100	37	100	212	100

Table 12: Main Drug of Use for New Agency NSP Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	1	1.6	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	8	13.1	0	0.0
Methadone	2	3.3	0	0.0
Steroids	50	82.0	1	33.3
Morphine	0	0.0	0	0.0
Cyclizine	0	0.0	1	33.3
Unknown	0	0.0	1	33.3
Total	61	100	3	100

Table 13: Main Drug of Use for All NSP Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	6	3.3	1	7.1
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	37	20.1	5	35.7
Methadone	15	8.2	2	14.3
Morphine	0	0.0	0	0.0
Steroids	124	67.4	1	7.1
Cyclizine	0	0.0	1	7.1
Various	0	0.0	2	14.3
Unknown	2	1.1	2	14.3
Total	184	100	14	100

Table 14: Year to Date; Main Drug of Use for All NSP Exchange Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	**n**	**%**	**n**	**%**
Amphetamines	17	3.5	1	2.2
Benzodiazepines	0	0.0	0	0.0
Cocaine	1	< 1	0	0.0
Crack	1	< 1	0	0.0
Heroin	125	25.8	22	47.8
Methadone	26	5.4	7	15.2
Morphine	0	0.0	0	0.0
Steroids	295	61.0	2	4.3
Cyclizine	3	< 1	2	4.3
Various	0	0.0	2	4.3
Unknown	16	3.3	10	21.7
Total	484	100	46	100

Table 15: Main Drug of Use for Agency Syringe Exchange Clients, by Age Group

	Ampheta-mine		Cocaine		Heroin		Methadone		Steroids		Unknown	
Age Group	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
Under 18	0	0.0	-	-	0	0.0	0	0.0	3	2.4	0	0.0
18-19	0	0.0	-	-	0	0.0	0	0.0	6	4.8	0	0.0
20-24	1	14.3	-	-	4	9.5	0	0.0	37	29.6	3	42.9
25-29	0	0.0	-	-	5	11.9	1	5.9	29	23.2	0	0.0
30-34	1	14.3	-	-	8	19.0	0	0.0	23	18.4	1	14.3
35-39	1	14.3	-	-	7	16.7	1	5.9	14	11.2	0	0.0
40-44	2	28.6	-	-	11	26.2	9	52.9	10	8.0	2	28.6
45+	2	28.6	-	-	7	16.7	6	35.3	3	2.4	1	14.3
Total	7	100	-	-	42	100	17	100	125	100	7	100

PHARMACY NSPs

Table 16: Individuals by Gender

New Clients	n	%
Male	231	90.9
Female	23	9.1
Total	254	100
All Clients		
Male	399	88.1
Female	54	11.9
Total	453	100

Table 17: Individuals by Site

	Individuals	
PNSP Site	**n**	**%**
Co-op Ormskirk St	93	20.5
Lloyd's Duke St	35	7.7
Lloyd's Sutton Oak	47	10.4
McDougalls Newton -le- Willows	0	0.0
Rowlands, Thatto Heath	6	1.3
St Helens Millenium Centre	272	60.1
Taylor's Haydock	0	0.0
Total	453	100

Table 18: Individuals by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	0	0.0	0	0.0
18-19	20	7.9	22	4.9
20-24	33	13.0	45	9.9
25-29	33	13.0	51	11.3
30-34	62	24.4	110	24.3
35-39	49	19.3	100	22.1
40-44	37	14.6	85	18.8
45+	20	7.9	40	8.8
Total	254	100	453	100

Table 19: Year to Date; by Gender & Age Group

Age Group	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	2	< 1	0	0.0	2	< 1
18-19	35	3.0	3	2.0	38	2.9
20-24	108	9.3	13	8.6	121	9.2
25-29	127	10.9	26	17.1	153	11.7
30-34	275	23.7	34	22.4	309	23.5
35-39	285	24.5	33	21.7	318	24.2
40-44	232	20.0	35	23.0	267	20.3
45+	97	8.4	8	5.3	105	8.0
Total	1,161	100	152	100	1,313	100

COMBINED PHARMACY AND AGENCY NSP

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 20: Individuals in Agency and Pharmacy NSP, by Gender

New Clients	n	%
Male	231	90.9
Female	23	9.1
Total	254	100
All Clients		
Male	399	88.1
Female	54	11.9
Total	453	100

Table 21: Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	222	90.6
Female	23	9.4
Total	245	100
All Clients		
Male	381	87.6
Female	54	12.4
Total	435	100

*Only known steroid users, based on Agency NSP data and some Pharmacy NSP, have been omitted.

Table 22: Individuals in Agency and Pharmacy NSP , by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	20	7.9	22	4.9
20-24	33	13.0	45	9.9
25-29	33	13.0	51	11.3
30-34	62	24.4	110	24.3
35-39	49	19.3	100	22.1
40-44	37	14.6	85	18.8
45+	20	7.9	40	8.8
Total	254	100	453	100

Table 23: Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	17	6.9	18	4.1
20-24	31	12.7	41	9.4
25-29	32	13.1	49	11.3
30-34	60	24.5	105	24.1
35-39	48	19.6	98	22.5
40-44	37	15.1	84	19.3
45+	20	8.2	40	9.2
Total	245	100	435	100

Table 24: Year to Date, by Gender & Age Group

Age Group	Gender				*Total in Age Group*	
	Male		Female			
	n	%	n	%	*n*	*%*
Under 18	2	0.1	0	0.0	2	0.1
18-19	52	3.7	6	3.4	58	3.7
20-24	169	12.0	15	8.6	184	11.6
25-29	181	12.8	31	17.8	212	13.4
30-34	319	22.6	35	20.1	354	22.3
35-39	322	22.8	40	23.0	362	22.8
40-44	255	18.0	34	19.5	289	18.2
45+	114	8.1	13	7.5	127	8.0
Total	1,414	100	174	100	1,588	1000

Table 25: Combined Pharmacy and Agency NSP Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	10,133	17,045	27,178	88,330

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

NSP SERVICE ACTIVITY SUMMARY

Data presented here illustrate service activity across all NSP types including number of transactions, proportion of data that are attributable and a split of activity by NSP type. Individuals by NSP type are also summarised for comparative purposes.

Table 26: All NSP transactions by NSP Type

All Transactions	n	%
St Helens CDT	557	29.8
Pharmacy NSPs	1,309	70.2
Total	1,866	100

Fig 1: NSP Service Activity; Transactions by NSP Type

Table 27: NSP Transactions, Attributable Data

All Attributable Transactions	n	%*
St Helens CDT	389	23.4
Pharmacy NSPs	1,272	76.6
Total	1,661	100

*Represents proportion of transactions that were attributable during the current quarter.

Table 28: PNSP Transactions and Individuals by Site

	Transactions		Individuals	
PNSP Site	**n**	**%**	**n**	**%**
Co-op Ormskirk St	247	18.9	93	20.5
Lloyd's Duke St	229	17.5	35	7.7
Lloyd's Sutton Oak	100	7.6	47	10.4
McDougalls Newton -le- Willows	0	0.0	0	0.0
Rowlands, Thatto Heath	17	1.3	6	1.3
St Helens Millenium Centre	716	54.7	272	60.1
Taylor's Haydock	0	0.0	0	0.0
Total	1,309	100	453	100

Table 29: All NSP Individuals by NSP Type

All Clients	**n**	**%**
St Helens CDT	198	30.4
Pharmacy NSPs	453	69.6
Total	651	100

Fig 2: NSP Service Activity; Individuals by NSP Type

National Drug Treatment Monitoring System (NDTMS)
Quarter 4 (2010/11)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or are in contact with treatment services, before this period.

Table 30: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	91	82.7
Female	19	17.3
Total	110	100
All Clients		
Male	805	77.0
Female	240	23.0
Total	1,045	100

Table 31: Year to Date, by Gender

New Clients	n	%
Male	300	79.4
Female	78	20.6
Total	378	100
All Clients		
Male	835	76.9
Female	251	23.1
Total	1,086	100

Table 32: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	8	7.3	93	8.9
18-19	2	1.8	16	1.5
20-24	8	7.3	105	10.0
25-29	20	18.2	195	18.7
30-34	26	23.6	219	21.0
35-39	22	20.0	190	18.2
40-44	16	14.5	139	13.3
45+	8	7.3	88	8.4
Total	110	100	1,045	100

Table 33: Year to Date, Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	52	13.8	112	10.3
18-19	8	2.1	19	1.7
20-24	35	9.3	107	9.9
25-29	58	15.3	191	17.6
30-34	76	20.1	228	21.0
35-39	73	19.3	194	17.9
40-44	52	13.8	142	13.1
45+	24	6.3	93	8.6
Total	378	100	1,086	100

Table 34: Ethnicity of Individuals in Contact with Treatment Services

	New Clients		All Clients	
Ethnicity	**n**	**%**	**n**	**%**
White British	108	98.2	1,024	98.0
White Irish	1	< 1	5	< 1
Other White	0	0.0	1	< 1
White & Black Caribbean	0	0.0	2	< 1
White & Asian	0	0.0	1	< 1
Other Mixed	0	0.0	1	< 1
Other Asian	0	0.0	2	< 1
Caribbean	0	0.0	1	< 1
Chinese	0	0.0	0	0.0
Other	1	< 1	4	< 1
Unknown	0	0.0	4	< 1
Total	110	100	1,045	100

Table 35: Individuals in Contact with Treatment Services, by Main Drug of Use

	New Clients		All Clients	
Drug of Use	**n**	**%**	**n**	**%**
Heroin	56	50.9	706	67.6
Methadone	17	15.5	84	8.0
Other Opiates	2	1.8	30	2.9
Benzodiazepines	0	0.0	10	1.0
Amphetamines	2	1.8	11	1.1
Cocaine	6	5.5	43	4.1
Crack	3	2.7	17	1.6
Hallucinogens	0	0.0	0	0.0
Ecstasy	0	0.0	1	< 1
Cannabis	12	10.9	114	10.9
Antidepressants	0	0.0	0	0.0
Prescription Drugs	12	10.9	21	2.0
Mephedrone	0	0.0	1	< 1
Other/Unknown	0	0.0	7	< 1
Total	110	100	1,045	100

COMBINED DATASETS

Quarter 4 (2010/11)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Needle & Syringe Programmes and NDTMS. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	1,245	81.5
Female	283	18.5
Age Group		
Under 18	96	6.3
18-19	42	2.7
20-24	180	11.8
25-29	251	16.4
30-34	322	21.1
35-39	278	18.2
40-44	224	14.7
45+	135	8.8
Total	1,528	100

Table 37: Year to Date, by Gender and Age Group

	Gender					
	Male		Female		Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	104	4.6	13	3.2	117	4.4
18-19	75	3.3	13	3.2	88	3.3
20-24	292	12.9	49	12.0	341	12.8
25-29	334	14.8	76	18.6	410	15.4
30-34	474	21.0	78	19.1	552	20.7
35-39	433	19.2	89	21.8	522	19.6
40-44	349	15.5	62	15.2	411	15.4
45+	197	8.7	28	6.9	225	8.4
Total	2,258	100	408	100	2,666	100

CROSS-MATCHED DATASETS

Quarter 4 (2010/11)

Data are shown for the crossover between each type of Needle and Syringe Programme and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of needle and syringe programme site.

**Fig 3: Current Quarter Crossover between Agency NSP and NDTMS datasets**

AGENCY (73) — Male 33 / Female 3 — NDTMS (1,045)

Fig 4: Current Quarter Crossover between Pharmacy NSP and NDTMS Datasets

PHARMACY (453) — Male 102 / Female 022 — NDTMS (1,045)

Fig 5: Year to Date Crossover between Agency NSP and NDTMS datasets

AGENCY (1,045)   Male 93 Female 18   NDTMS (1,086)

Fig 6: Year to Date Crossover between Pharmacy NSP and NDTMS datasets

PHARMACY (1,313)   Male 188 Female 36   NDTMS (1,086)